Stock Events

Stock Events

Xintela AB 

€0.01
1
-€0-14.52% Today

Statistics

Day High
0.01
Day Low
0.01
52W High
0.06
52W Low
0.01
Volume
-
Avg. Volume
-
Mkt Cap
7.42M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.02
-0.02
-0.01
-0.01
Expected EPS
-0.0097395212
Actual EPS
N/A

Financials

-928.38%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
739,005.68Revenue
-6.86MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1XT.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap2.01B
Mesoblast Limited operates in the regenerative medicine industry, developing stem cell-based therapies that overlap with Xintela's market.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap7.06M
Brainstorm Cell Therapeutics Inc is involved in stem cell technology for neurodegenerative diseases, competing in the broader stem cell therapy sector.
Vericel
VCEL
Mkt Cap1.82B
Vericel Corporation produces regenerative medicines for repairing damaged tissues, a direct competitor in Xintela's operational field.

About

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. It has an agreement with Region Östergötland for GMP process development of cell therapy for burn patients. Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Show more...
CEO
Mr. Gregory Batcheller B.Sc., J.D., L.L.M.
Employees
13
Country
Sweden
ISIN
SE0007756903
WKN
000A2AF7J

Listings

F
DE
1XT.F
ST
SE
XINT.ST

0 Comments

Share your thoughts

FAQ

What is Xintela AB stock price today?▼
The current price of 1XT.F is €0.01 EUR — it has decreased by -14.52% in the past 24 hours. Watch Xintela AB stock price performance more closely on the chart.
What is Xintela AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xintela AB stocks are traded under the ticker 1XT.F.
Is Xintela AB stock price growing?▼
1XT.F stock has fallen by -28.38% compared to the previous week, the month change is a +8.16% rise, over the last year Xintela AB has showed a -60.15% decrease.
What is Xintela AB market cap?▼
Today Xintela AB has the market capitalization of 7.42M
When is the next Xintela AB earnings date?▼
Xintela AB is going to release the next earnings report on May 22, 2026.
What were Xintela AB earnings last quarter?▼
1XT.F earnings for the last quarter are -0 EUR per share, whereas the estimation was -0 EUR resulting in a -100% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Xintela AB revenue for the last year?▼
Xintela AB revenue for the last year amounts to 739,005.68 EUR.
What is Xintela AB net income for the last year?▼
1XT.F net income for the last year is -6.86M EUR.
How many employees does Xintela AB have?▼
As of April 29, 2026, the company has 13 employees.
In which sector is Xintela AB located?▼
Xintela AB operates in the Health & Wellness sector.
When did Xintela AB complete a stock split?▼
Xintela AB has not had any recent stock splits.
Where is Xintela AB headquartered?▼
Xintela AB is headquartered in Lund, Sweden.